QuidelOrtho Corporation (NASDAQ: QDEL) Securities Class Action: The litigation is focused on the propriety of QuidelOrtho's past assurances about its preparedness to maintain a stable high margin revenue stream from its respiratory business in the face of the COVID-19 pandemic becoming an endemic and about its FDA submission for its purported "next flagship product" (the "Savanna RVP4 Test") being "on track." On Apr. 2, 2024, the price of QuidelOrtho shares fell $4.85 (10%) after the company announced that ...

CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171 www.zlk.com CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (a) that QuidelOrtho sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare providers and end customers; (b) that excess inventories of COVID-19 tests existed th ...

On this news, QuidelOrtho's stock price fell $4.85 per share, or over 10%, to close at $42.15 per share on April 2, 2024. If you wish to serve as lead plaintiff, you must move the Court no later than June 11, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member. If you purchased or acqui ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 03, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises QuidelOrtho Corporation ("QuidelOrtho" or the "Company") (NASDAQ: QDEL) investors who purchased common stock between February 18, 2022 and April 1, 2024, inclusive (the "Class Period") to visit our website. On February 13, 2024, QuidelOrtho released its fourth quarter 2023 financial results, reporting Adjusted Earnings Per Share that were 46% b ...

Case Details: According to the Complaint, QuidelOrtho provides tests for the detection and diagnosis of various respiratory diseases and other medical conditions. The Company's respiratory business has historically been tied to the sale of seasonal flu tests and more recently to COVID-19 detection tests. Since the onset of the COVID-19 pandemic, the Company has generated a significant portion of its revenue through the sale of COVID-19 tests to government customers, healthcare providers (through its authori ...

NEW YORK, May 30, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against QuidelOrtho Corporation ("QuidelOrtho" or the "Company") (NASDAQ: QDEL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether QuidelOrtho and certain of ...

NEW YORK, May 30, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in QuidelOrtho Corporation f/k/a Quidel Corporation ("QuidelOrtho" or the "Company") (NASDAQ: QDEL) of a class action securities lawsuit. WHAT'S NEXT? If you suffered a loss in QuidelOrtho during the relevant time frame, you have until June 11, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class ...

NEW YORK, May 29, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation (NASDAQ: QDEL). Shareholders who purchased shares of QDEL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/quidelortho-loss-submission-form/?id=81721&from=4 CLAS ...

BENSALEM, Pa., May 23, 2024 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or the "Company") (NASDAQ: QDEL). Class Period: February 18, 2022 – April 1, 2024 Lead Plaintiff Deadline: June 11, 2024 To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absen ...

NEW YORK, May 23, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in QuidelOrtho Corporation f/k/a Quidel Corporation ("QuidelOrtho" or the "Company") (NASDAQ: QDEL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of QuidelOrtho investors who were adversely affected by alleged securities fraud between February 18, 2022 and April 1, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/ ...